Current use of CAR T cells to treat multiple myeloma

2.

Munshi

NC

,

Anderson

LD

Jr,

Shah

N

, et al.

Idecabtagene vicleucel in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2021

;

384

(

8

):

705

-

716

.

doi:10.1056/NEJMoa2024850

.

3.

Berdeja

JG

,

Madduri

D

,

Usmani

SZ

, et al.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

.

Lancet

.

2021

;

398

(

10297

):

314

-

324

.

doi:10.1016/S0140-6736(21)00933-8

.

4.

Moreau

P

,

Garfall

AL

,

van de Donk

NWCJ

, et al.

Teclistamab in relapsed or refractory multiple myeloma

.

N Engl J Med

.

2022

;

387

(

6

):

495

-

505

.

doi:10.1056/NEJMoa2203478

.

5.

Chari

A

,

Minnema

MC

,

Berdeja

JG

, et al.

Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma

.

N Engl J Med

.

2022

;

387

(

24

):

2232

-

2244

.

doi:10.1056/NEJMoa2204591

.

6.

Raje

NS

,

Siegel

DS

,

Jagannath

S

, et al.

Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa Study

.

Blood

.

2020

;

136

(

suppl 1

):

37

-

38

.

doi:10.1182/blood-2020-134319

.

7.

Jakubowiak

A

,

Usmani

SZ

,

Berdeja

JG

, et al.

Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 subgroup analysis

.

Blood

.

2021

;

138

(

suppl 1

):

3938

.

doi:10.1182/blood-2021-146069

.

8.

Gandhi

UH

,

Cornell

RF

,

Lakshman

A

, et al.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

.

Leukemia

.

2019

;

33

(

9

):

2266

-

2275

.

doi:10.1038/s41375-019-0435-7

.

9.

Vogl

DT

,

Dingli

D

,

Cornell

RF

, et al.

Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma

.

J Clin Oncol

.

2018

;

36

(

9

):

859

-

866

.

doi:10.1200/JCO.2017.75.5207

.

10.

Hansen

DK

,

Sidana

S

,

Peres

LC

, et al.

Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium

.

J Clin Oncol

.

2023

;

41

(

11

):

2087

-

2097

.

doi:10.1200/JCO.22.01365

.

11.

Jagannath

S

,

Lin

Y

,

Goldschmidt

H

, et al.

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

.

Blood Cancer J

.

2021

;

11

(

6

):

116

.

doi:10.1038/s41408-021-00507-2

.

12.

Hansen

DK

,

Patel

KK

,

Peres

LC

, et al.

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM)

.

J Clin Oncol

.

2023

;

41

(

16, suppl

):

8012

.

doi:10.1200/JCO.2023.41.16_suppl.8012

.

13.

San-Miguel

J

,

Dhakal

B

,

Yong

K

, et al.

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

.

N Engl J Med

.

2023

;

389

(

4

):

335

-

347

.

doi:10.1056/NEJMoa2303379

.

14.

Mohyuddin

GR

,

Atieh

T

,

Ahmed

N

, et al.

Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: a systematic review and meta-analysis

.

Eur J Cancer

.

2021

;

156

:

164

-

174

.

doi:10.1016/j.ejca.2021.07.036

.

15.

Mailankody

S

,

Matous

JV

,

Chhabra

S

, et al.

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

.

Nat Med

.

2023

;

29

(

2

):

422

-

429

.

doi:10.1038/s41591-022-02182-7

.

16.

Lee

DW

,

Santomasso

BD

,

Locke

FL

, et al.

ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells

.

Biol Blood Marrow Transplant

.

2019

;

25

(

4

):

625

-

638

.

doi:10.1016/j.bbmt.2018.12.758

.

17.

Cohen

AD

,

Parekh

S

,

Santomasso

BD

, et al.

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

.

Blood Cancer J

.

2022

;

12

(

2

):

32

.

doi:10.1038/s41408-022-00629-1

.

18.

Thibaud

S

,

Mia

MdB

,

Van Oekelen

O

, et al.

Comprehensive characterization of prolonged unexplained cytopenias in relapsed/refractory multiple myeloma patients following BCMA-directed CAR-T cell therapy

.

Blood

.

2022

;

140

(

suppl 1

):

614

-

616

.

doi:10.1182/blood-2022-165646

.

19.

Rodriguez-Otero

P

,

Ailawadhi

S

,

Arnulf

B

, et al.

Ide-cel or standard regimens in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2023

;

388

(

11

):

1002

-

1014

.

doi:10.1056/NEJMoa2213614

.

20.

Stewart

AK

,

Rajkumar

SV

,

Dimopoulos

MA

, et al;

ASPIRE Investigators

.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

.

N Engl J Med

.

2015

;

372

(

2

):

142

-

152

.

doi:10.1056/NEJMoa1411321

.

21.

Moreau

P

,

Dimopoulos

M-A

,

Mikhael

J

, et al;

IKEMA study group

.

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

.

Lancet

.

2021

;

397

(

10292

):

2361

-

2371

.

doi:10.1016/S0140-6736(21)00592-4

.

22.

Dimopoulos

M

,

Quach

H

,

Mateos

M-V

, et al.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

.

Lancet

.

2020

;

396

(

10245

):

186

-

197

.

doi:10.1016/S0140-6736(20)30734-0

.

23.

Mikhael

J

,

Belhadj-Merzoug

K

,

Hulin

C

, et al.

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

.

Blood Cancer J

.

2021

;

11

(

5

):

89

.

doi:10.1038/s41408-021-00478-4

.

24.

Da Vià

MC

,

Dietrich

O

,

Truger

M

, et al.

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

.

Nat Med

.

2021

;

27

(

4

):

616

-

619

.

doi:10.1038/s41591-021-01245-5

.

25.

Samur

MK

,

Fulciniti

M

,

Aktas Samur

A

, et al.

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

.

Nat Commun

.

2021

;

12

(

1

):

868

.

doi:10.1038/s41467-021-21177-5

.

26.

Lee

H

,

Ahn

S

,

Maity

R

, et al.

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

.

Nat. Med

.

2023

;

29

(

9

):

2295

-

2306

.

doi:10.21203/rs.3.rs-2657360/v1

.

27.

Cohen

AD

,

Mateos

M-V

,

Cohen

Y-C

, et al.

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

.

Blood

.

2023

;

141

(

3

):

219

-

230

.

doi:10.1182/blood.2022015526

.

28.

Kumar

S

,

Paiva

B

,

Anderson

KC

, et al.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

.

Lancet Oncol

.

2016

;

17

(

8

):

e328

-

e346

.

doi:10.1016/S1470-2045(16)30206-6

.

29.

Bansal

R

,

Baksh

M

,

Larsen

JT

, et al.

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma

.

Blood Cancer J

.

2023

;

13

(

1

):

47

.

doi:10.1038/s41408-023-00820-y

.

30.

Jagannath

S

,

Joseph

N

,

Crivera

C

, et al.

Component costs of CAR-T therapy in addition to treatment acquisition costs in patients with multiple myeloma

.

Oncol Ther

.

2023

;

11

(

2

):

263

-

275

.

doi:10.1007/s40487-023-00228-5

.

31.

Wu

W

,

Ding

S

,

Mingming

Z

, et al.

Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China

.

J Med Econ

.

2023

;

26

(

1

):

701

-

709

.

doi:10.1080/13696998.2023.2207742

.

32.

Kapinos

KA

,

Hu

E

,

Trivedi

J

,

Geethakumari

PR

,

Kansagra

A

.

Cost-effectiveness analysis of CAR T-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma

.

Cancer Control

.

2023

;

30

:

10732748221142945

.

doi:10.1177/10732748221142945

.

33.

Mailankody

S

,

Devlin

SM

,

Landa

J

, et al.

GPRC5D-targeted CAR T cells for myeloma

.

N Engl J Med

.

2022

;

387

(

13

):

1196

-

1206

.

doi:10.1056/NEJMoa2209900

.

34.

Xia

J

,

Li

H

,

Yan

Z

, et al.

Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial

.

J Clin Oncol

.

2023

;

41

(

14

):

2583

-

2593

.

doi:10.1200/JCO.22.01824

.

35.

Zhang

M

,

Wei

G

,

Zhou

L

, et al.

GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial

.

Lancet Haematol

.

2023

;

10

(

2

):

e107

-

e116

.

doi:10.1016/S2352-3026(22)00372-6

.

36.

Van Oekelen

O

,

Nath

K

,

Mouhieddine

TH

, et al.

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

.

Blood

.

2023

;

141

(

7

):

756

-

765

.

doi:10.1182/blood.2022017848

.

37.

Du

J

,

Fu

W-J

,

Jiang

H

, et al.

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)

.

J Clin Oncol

.

2023

;

41

(

16, suppl

):

8005

.

doi:10.1200/JCO.2023.41.16_suppl.8005

.

38.

Firestone

R

,

Shekarkhand

T

,

Patel

D

, et al.

Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies

.

J Clin Oncol

.

2023

;

41

(

16, suppl

):

8049

.

doi:10.1200/JCO.2023.41.16_suppl.8049

.

39.

Lin

Y

,

Martin

TG

,

Usmani

SZ

, et al.

CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

.

J Clin Oncol

.

2023

;

41

(

16, suppl

):

8009

.

doi:10.1200/JCO.2023.41.16_suppl.8009

.